Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,840,000 shares, a growth of 8.2% from the December 15th total of 3,550,000 shares. Based on an average daily volume of 463,300 shares, the short-interest ratio is currently 8.3 days.
Aldeyra Therapeutics Trading Up 1.3 %
Shares of Aldeyra Therapeutics stock traded up $0.06 during mid-day trading on Friday, hitting $4.84. 274,810 shares of the stock were exchanged, compared to its average volume of 370,307. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The company has a 50-day simple moving average of $4.94 and a 200 day simple moving average of $4.97. Aldeyra Therapeutics has a 12 month low of $2.71 and a 12 month high of $6.55.
Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). On average, sell-side analysts forecast that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.
Institutional Trading of Aldeyra Therapeutics
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
See Also
- Five stocks we like better than Aldeyra Therapeutics
- What is MarketRank™? How to Use it
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- 10 Best Airline Stocks to Buy
- Oilfield Leader SLB: An AI Name You Need to Know
- What is a Death Cross in Stocks?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.